LAUSANNE, Switzerland, Dec. 17, 2021 /PRNewswire/ — Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123, an oral, potent and highly selective WEE1 inhibitor, as monotherapy in patients with advanced solid tumors (NCT05109975). Part of